BLAINJECTIONINJECTABLE
Approved
Aug 2017
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CYLTEZO (adalimumab-adbm) is a monoclonal antibody TNF-alpha inhibitor approved in 2017 as a biosimilar to reference adalimumab. It treats eight inflammatory and autoimmune indications including rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, and psoriatic arthritis by blocking TNF-alpha signaling and reducing inflammatory cell infiltration. The drug works by binding TNF-alpha and blocking its interaction with p55 and p75 cell surface receptors, modulating adhesion molecules responsible for leukocyte migration.
Peak
As a maturing peak-stage biosimilar in a competitive TNF-inhibitor class, the CYLTEZO team is likely focused on market penetration and defensive positioning against newer mechanism competitors rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CYLTEZO positions you in the competitive biosimilar and TNF-inhibitor space at Boehringer Ingelheim, where career growth depends on market penetration against entrenched competitors and emerging mechanisms rather than clinical innovation. Roles emphasize commercial execution, payer management, and competitive intelligence in a mature, price-sensitive segment with declining reimbursement and market share pressure.
Brand Manager
Worked on CYLTEZO at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.